Elo Mutual Pension Insurance Co Sells 6,870 Shares of DexCom, Inc. $DXCM

Elo Mutual Pension Insurance Co trimmed its stake in DexCom, Inc. (NASDAQ:DXCM) by 14.7% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 39,918 shares of the medical device company’s stock after selling 6,870 shares during the period. Elo Mutual Pension Insurance Co’s holdings in DexCom were worth $3,484,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in DXCM. Laurel Wealth Advisors LLC increased its position in shares of DexCom by 8,629.1% during the second quarter. Laurel Wealth Advisors LLC now owns 63,548 shares of the medical device company’s stock worth $5,547,000 after buying an additional 62,820 shares during the period. Edmond DE Rothschild Holding S.A. raised its position in DexCom by 4,625.9% in the 2nd quarter. Edmond DE Rothschild Holding S.A. now owns 63,800 shares of the medical device company’s stock valued at $5,569,000 after buying an additional 62,450 shares during the last quarter. Picton Mahoney Asset Management increased its stake in DexCom by 41.9% in the 2nd quarter. Picton Mahoney Asset Management now owns 204,060 shares of the medical device company’s stock valued at $17,812,000 after buying an additional 60,291 shares during the last quarter. Global Retirement Partners LLC purchased a new stake in shares of DexCom during the 2nd quarter valued at $472,000. Finally, Charles Schwab Investment Management Inc. raised its holdings in shares of DexCom by 2.9% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 3,073,266 shares of the medical device company’s stock worth $268,265,000 after purchasing an additional 85,610 shares during the period. Institutional investors and hedge funds own 97.75% of the company’s stock.

Insider Activity at DexCom

In other news, Director Kyle Malady sold 667 shares of the stock in a transaction on Friday, September 5th. The shares were sold at an average price of $80.86, for a total value of $53,933.62. Following the sale, the director owned 22,667 shares of the company’s stock, valued at approximately $1,832,853.62. This represents a 2.86% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Jacob Steven Leach acquired 18,200 shares of DexCom stock in a transaction that occurred on Monday, November 10th. The stock was purchased at an average cost of $55.04 per share, for a total transaction of $1,001,728.00. Following the completion of the transaction, the chief operating officer directly owned 331,697 shares in the company, valued at $18,256,602.88. This trade represents a 5.81% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders sold a total of 9,999 shares of company stock valued at $619,391 over the last ninety days. 0.32% of the stock is currently owned by company insiders.

DexCom Trading Up 1.4%

Shares of DexCom stock opened at $62.53 on Thursday. The firm has a market cap of $24.39 billion, a price-to-earnings ratio of 43.42, a PEG ratio of 1.43 and a beta of 1.40. The business has a 50-day moving average price of $64.66 and a 200-day moving average price of $76.13. The company has a quick ratio of 1.35, a current ratio of 1.52 and a debt-to-equity ratio of 0.48. DexCom, Inc. has a twelve month low of $54.11 and a twelve month high of $93.25.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, October 30th. The medical device company reported $0.61 EPS for the quarter, beating analysts’ consensus estimates of $0.57 by $0.04. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The firm had revenue of $1.21 billion during the quarter, compared to the consensus estimate of $1.18 billion. During the same period in the prior year, the company earned $0.45 EPS. The company’s quarterly revenue was up 21.6% compared to the same quarter last year. DexCom has set its FY 2025 guidance at EPS. Equities research analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts recently weighed in on DXCM shares. Canaccord Genuity Group set a $99.00 price objective on shares of DexCom and gave the company a “buy” rating in a research note on Friday, October 31st. Royal Bank Of Canada dropped their price target on DexCom from $100.00 to $85.00 and set an “outperform” rating for the company in a research note on Friday, October 31st. Raymond James Financial upped their price objective on shares of DexCom from $99.00 to $102.00 and gave the company a “strong-buy” rating in a research note on Thursday, July 31st. Wells Fargo & Company set a $93.00 price target on DexCom and gave the stock an “overweight” rating in a research report on Friday, October 31st. Finally, UBS Group cut their price target on shares of DexCom from $106.00 to $95.00 and set a “buy” rating on the stock in a report on Monday, November 3rd. Three research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, DexCom has a consensus rating of “Moderate Buy” and an average target price of $86.73.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.